Clinical DevelopmentsThe FDA lifted the clinical hold on 0.25 and 0.5mg doses of VYN202 for female patients, offering encouraging proof-of-concept for VYN202 and highlighting its potential across various autoimmune indications.
Financial PositionThe company ends this trial in a relatively stable financial position, with approximately $40 million in cash to extend operations or deploy strategically.
Preclinical DataVYN202 has demonstrated promising preclinical data across multiple models of fibro-inflammatory disease and hematologic malignancies.